Ongoing Clinical Trials for Dermatitis
This article provides information about 2 ongoing clinical trials investigating new treatments for dermatitis and related inflammatory skin conditions. These studies are evaluating different targeted therapies aimed at reducing inflammation and improving symptoms in patients who have not responded well to standard treatments.
Clinical trial locations
- France
- Germany
Study on Ustekinumab and Drug Combination for Patients with Severe, Resistant Inflammatory Disease
This clinical trial, taking place in France, focuses on patients with severe inflammatory disease that affects multiple organs and has not responded to standard treatments. The condition must involve the skin along with at least one other organ system.
Main inclusion criteria: Participants must be 18 years or older with a non-classified inflammatory disease affecting at least two body systems, with mandatory skin involvement. The disease must significantly impact quality of life and must have been resistant to at least two previous treatments, such as hydroxychloroquine, methotrexate, or corticosteroids. Patients must provide signed informed consent to participate.
Main exclusion criteria: Patients who fall into vulnerable populations or who do not meet the specific age and clinical trial group requirements cannot participate in the study.
Study focus: The trial aims to evaluate personalized treatments selected based on detailed analysis of each patient’s specific inflammatory pathways. The main goal is to determine whether there is improvement in disease activity, particularly in the skin and other affected areas, at six months after treatment begins. The study will monitor changes in symptoms and biological markers of inflammation.
Investigational treatments: The study tests several medications including Ustekinumab, Secukinumab, Adalimumab, Anakinra, Rituximab, and Tocilizumab. These medications are administered through injections, either under the skin or directly into the bloodstream. Each medication works by targeting specific parts of the immune system to reduce inflammation. The treatment approach is personalized using an algorithm based on molecular analysis of the patient’s inflammatory pathways, referred to as PIMOC therapy.
Study on Dupilumab for Treating Nummular Eczema in Patients
This clinical trial, conducted in Germany, is studying the effectiveness of Dupilumab for treating nummular eczema, a type of skin condition that causes round, itchy patches on the skin.
Main inclusion criteria: Participants must have a clinically and biopsy-confirmed diagnosis of nummular eczema. The condition must be moderate to severe, with an EASI score of 10 or higher and a Physician’s Global Assessment score of 3 or higher on a 5-point scale. Patients must have used at least mid-potency topical steroids continuously for the last 8 weeks. Participants must be between 18 and 85 years old, weigh between 40 kg and 160 kg, and provide signed informed consent. Female participants of childbearing potential must have a negative pregnancy test and use medically approved contraception.
Main exclusion criteria: Patients who do not have nummular eczema cannot participate in the study.
Study focus: The trial evaluates how effective Dupilumab is in treating nummular eczema over a 16-week period. This is a double-blind study, meaning neither participants nor researchers know who receives the actual medication or a placebo. Regular assessments will monitor changes in eczema severity, overall skin health, quality of life, and any side effects or adverse reactions.
Investigational drug: Dupilumab is administered as a 300 mg solution injected under the skin at regular intervals. It works by blocking certain proteins in the body that cause inflammation, helping to reduce symptoms like redness, itching, and skin patches. Dupilumab is classified as a monoclonal antibody, a type of medication designed to target specific molecules in the immune system.
Summary
These two ongoing clinical trials represent different approaches to treating inflammatory skin conditions. The French study takes a personalized medicine approach, using molecular analysis to select from multiple treatment options for patients with complex, multi-organ inflammatory disease. In contrast, the German trial focuses specifically on one medication, Dupilumab, for a well-defined skin condition, nummular eczema.
Both trials target patients who have not responded adequately to standard treatments, offering hope for those with difficult-to-treat conditions. The French study is particularly notable for testing six different medications in a personalized approach, while the German study provides a more focused evaluation of a single therapy. These geographical differences also highlight the international nature of clinical research, with each country contributing to our understanding of effective treatments for inflammatory skin conditions.
